Articles from Protagenic Therapeutics, Inc.

$1.5 million upfront financing, along with up to $3.5 million upon exercise of milestone-linked warrants, is expected to fund IND-enabling activities and initiation of the Phase 1/2a trial of PT00114Phase 1/2a design is intended to generate both safety data and an early efficacy signal in patients with GAD within a single studyIND submission targeted for late Q1 2027, incorporating FDA's pre-IND requests; first patient dosing targeted for Q2 2027, consistent with the Company's previously announced first-half 2027 timelineTopline safety data expected in 2H 2027; exploratory efficacy data expected in 1H 2028

FDA raises no objection to the Company's planned Phase 1 program design, dose-escalation approach, or CMC and nonclinical packages; IND submission remains on track for the fourth quarter of 2026

As published in Behavioural Pharmacology, two days of PT00114 treatment reduced corticosterone levels and attenuated anxiety-like behavior in chronically stressed rats; a known CRF₁ receptor antagonist did not show activity in the same model.

NEW YORK, NY / ACCESSWIRE / April 26, 2022 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a biopharmaceutical company focused on developing drug product candidates to treat stress-related neurologic disorders, today announced will be presenting at the B. Riley Securities Neuro and Ophthalmology Virtual Investor Conference tomorrow, April 27, 2022. The presentation details are as follows: Date: Wednesday, April 27, 2022 Time: 10:30 AM ET Link: